Demant officially completed the divestment of its bone-anchored hearing solutions business, Oticon Medical, to the Stockholm based investment company, Impilo , on March 31, 2026. The sale followed the 2024 sale of Demant’s cochlear implant business to Cochlear. The divestment to Impilo covers the entirety of the Oticon Medical business that was left after the sale to Cochlear....
No actionable change for clinical practice; this is a corporate ownership change that may affect supplier relationships or product support over time, but requires no immediate clinical response.
Demant's complete exit from implantable hearing solutions reshapes the competitive landscape for bone-anchored and cochlear implant markets, potentially affecting clinician supplier choices and long-term product continuity.
- 01Demant completed the sale of Oticon Medical (bone-anchored hearing solutions) to Swedish firm Impilo on March 31, 2026.
- 02The cochlear implant arm of Oticon Medical was separately sold to Cochlear in 2024.
- 03Demant has now fully divested all implantable hearing device businesses.
- 04Impilo is a Stockholm-based investment firm, not an existing hearing industry incumbent.
- 05The move signals a strategic refocus by Demant on its core hearing aid and audiological care businesses.
Demant completed the divestment of Oticon Medical to Impilo on March 31, 2026.
press releasesupportedDemant previously sold its cochlear implant business to Cochlear in 2024.
press releasesupported
